Cisplatin, doxorubicin, cyclophosphamide, lomustine, and vincristine (PACCO) in the treatment of non-small cell bronchogenic carcinoma.

Abstract

A total of 43 patients with non-small cell carcinoma from a small preliminary trial and a larger in-house study were evaluated after treatment with cisplatin (50 mg/m2), doxorubicin (50 mg/m2), cyclophosphamide (300 mg/m2), and vincristine (1.4 mg/m2), all given iv on Day 1, and lomustine (50 mg/m2) given orally on Day 1. The response rate in the larger trial was 9%, with a 95% confidence interval of 2%-24%. For the combined group of all patients, median survival was 200 days, with a 95% confidence interval of 115-229 days. Hematologic toxicity and nausea and vomiting were moderate to severe and there were two treatment-related deaths. This combination drug regimen appears to have no advantages over other, less toxic regimens in the treatment of non-small cell bronchogenic carcinoma.

• Authors: R P Whitehead, P R Rosenbaum, P P Carbone
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 68 Issue 5 Pg. 771-3 (May 1984) ISSN: 0361-5960 [Print] United States
• PMID: 6539171 (Publication Type: Journal Article)

Chemical References

• Vincristine
• Lomustine
• Doxorubicin
• Cyclophosphamide
• Cisplatin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use, toxicity)
• Carcinoma, Bronchogenic (drug therapy, pathology)
• Cisplatin (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Evaluation
• Hematologic Diseases (chemically induced)
• Humans
• Lomustine (administration & dosage)
• Lung Neoplasms (drug therapy, pathology)
• Nausea (chemically induced)
• Time Factors
• Vincristine (administration & dosage)